CBLL
HealthcareCeriBell, Inc. · Medical - Devices · $710M
What is CeriBell, Inc.?
CeriBell, Inc. is a small-cap healthcare company focused on bringing AI-powered electroencephalography to the point of care. Based in Sunnyvale, California, the company targets the acute care setting where rapid neurological assessment is critical.
CeriBell develops the Ceribell System, a point-of-care EEG platform designed to detect seizures and other neurological conditions in acute care environments — settings where traditional EEG equipment is often unavailable or too slow to deploy. The company generates revenue through its EEG platform and recurring sales of disposable headbands used with the system. A pocket-sized, battery-operated recorder makes the technology portable and accessible to clinicians outside of specialized neurology departments.
CeriBell was incorporated in 2014 and is headquartered in Sunnyvale, California.
- Ceribell System — AI-powered point-of-care EEG platform
- Disposable EEG headbands for single-patient use
- Pocket-sized battery-operated EEG recorder
- AI-driven seizure detection software for acute care
Is CBLL a Good Stock to Buy?
UQS Score rates CBLL as Below Average overall, reflecting a mixed profile where strong growth potential is offset by meaningful structural weaknesses.
The Growth pillar stands out as the clearest positive signal — CeriBell operates in an underpenetrated market with a differentiated product addressing a genuine clinical gap. The Risk pillar also registers as Good, suggesting the company's near-term financial stability is relatively manageable for its stage.
Both the Quality and Moat pillars score as Weak, indicating limited profitability and a competitive position that has yet to be firmly established. Valuation is rated Elevated, meaning the current price already reflects considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CBLL pay dividends?
No — CeriBell, Inc. does not currently pay a dividend.
CeriBell does not currently pay a dividend. As an early-stage medical technology company, capital is directed toward product development, clinical adoption, and market expansion rather than shareholder distributions. Investors in CBLL are typically seeking growth rather than income.
When does CBLL report earnings?
CeriBell reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
As an emerging medical device company, CeriBell's quarterly results are closely watched for signs of commercial traction and progress toward profitability. Revenue growth trends and cash utilization are key metrics investors monitor each reporting period.
For the most recent quarter's results and guidance, visit CeriBell's investor relations page directly.
CBLL Price History
-20.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in CeriBell, Inc.?
Based on CeriBell, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CBLL Long-term Outlook
CeriBell's Growth pillar rating of Strong reflects genuine commercial momentum in a market with limited direct competition at the point-of-care EEG level. However, the Weak Quality and Moat ratings serve as a reminder that translating growth into durable profitability remains the central challenge. The Elevated Valuation pillar suggests the market has already priced in a favorable trajectory, leaving little room for execution missteps. The Good Risk rating provides some reassurance around near-term financial resilience.
Growth drivers
- Expansion of AI-powered EEG into underpenetrated acute care settings
- Recurring revenue from disposable headband consumables
- Growing clinical awareness of non-convulsive seizure detection needs
Key risks
- Weak Moat rating signals vulnerability to better-resourced competitors entering the space
- Elevated Valuation leaves limited margin of safety if growth disappoints
- Path to profitability remains uncertain given Weak Quality pillar
CBLL vs Peers
CeriBell operates in the broader medical technology and neurology device space, where it competes indirectly with established healthcare companies.
Integra is a diversified neurosurgery and regenerative medicine company with a much broader product portfolio and longer commercial history than CeriBell.
Bioventus focuses on orthobiologics and surgical solutions, representing a different segment of the medical device market but competing for similar hospital budget allocations.
InMode develops minimally invasive energy-based medical technologies, operating in aesthetics and wellness rather than neurology, but sharing the small-cap medtech growth profile.
Frequently Asked Questions
What does CeriBell do?
CeriBell develops AI-powered point-of-care EEG technology designed to detect seizures and neurological conditions in acute care settings. Its flagship Ceribell System brings rapid EEG assessment to hospital environments where traditional neurology equipment is not readily available, supported by disposable headbands and a portable recorder.
Does CBLL pay dividends?
No, CeriBell does not currently pay a dividend. The company is in a growth phase and directs available capital toward expanding its technology platform and commercial footprint rather than returning cash to shareholders.
When does CBLL report earnings?
CeriBell follows a standard quarterly earnings cadence for US-listed companies. For exact reporting dates and the most recent financial results, check CeriBell's official investor relations page.
Is CBLL a good stock to buy?
UQS Score rates CBLL as Below Average overall. The Growth pillar is Strong and the Risk pillar is Good, but both Quality and Moat are Weak, and Valuation is Elevated. Whether it suits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.
Is CBLL overvalued?
The UQS Valuation pillar for CBLL is rated Elevated, suggesting the current market price reflects significant growth expectations already. Investors should weigh this against the company's early-stage profitability profile before drawing conclusions.
How does CBLL compare to its competitors?
CeriBell is a focused point-of-care neurology company, which differentiates it from broader medtech peers like Integra LifeSciences. Its niche AI-EEG positioning is distinctive, but its Weak Moat rating indicates the competitive advantage is not yet firmly entrenched. Full peer comparisons are available to UQS Pro members.
What is CBLL's market cap bracket?
CeriBell is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded CeriBell?
CeriBell was originally incorporated under the name Brain Stethoscope, Inc. before rebranding in August 2015. Founding details are publicly available through the company's official disclosures and SEC filings for those seeking the full history.
Is CBLL a long-term quality investment?
From a long-term quality perspective, CBLL's UQS profile is mixed. The Strong Growth pillar points to real commercial opportunity, but Weak Quality and Moat ratings suggest the business has not yet built the durable financial characteristics typically associated with long-term compounders. Monitoring pillar progression over time is advisable.
What is the main competitive advantage of CeriBell?
CeriBell's primary differentiation lies in its AI-driven, point-of-care EEG system that makes rapid neurological assessment accessible outside of specialized settings. However, the UQS Moat pillar is currently rated Weak, indicating this advantage has not yet translated into a firmly defensible market position.
What sector does CBLL belong to?
CeriBell operates in the Healthcare sector, specifically within medical technology and neurology devices. It targets acute care hospitals and clinical settings where fast, accurate seizure detection can meaningfully affect patient outcomes.
Is CBLL a growth stock or value stock?
Based on its UQS profile, CBLL leans firmly toward the growth category — the Growth pillar is rated Strong while Valuation is Elevated, a combination typical of early-stage companies where the market prices in future potential rather than current earnings power.
Unlock Full CBLL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare CBLL against sector peers side by side
- ✓Screen for stocks with stronger Quality and Moat ratings
- ✓Get the full analyst-grade breakdown in one place
Pro Analysis
CBLL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 44.7 | 16.7 | 39.0 | 100.0 | 71.9 | 0.0 | +4.2 |
| May 8, 2026 | 40.5 | 0.0 | 39.0 | 100.0 | 71.9 | 0.0 | -4.2 |
| Apr 2, 2026 | 44.7 | 16.7 | 39.0 | 100.0 | 71.9 | 0.0 | — |
CBLL — Pillar Breakdown
Quality
— 16.7/100 (25%)CeriBell, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)CeriBell, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.9/100 (15%)CeriBell, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)CeriBell, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 39/100 (25%)CeriBell, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CBLL.
Score Composition
Financial Data
More Stock Analysis
How is the CBLL UQS Score Calculated?
The UQS (Unified Quality Score) for CeriBell, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses CeriBell, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether CeriBell, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.